BLLN (BillionToOne) PE Ratio without NRI: 149.92 (As of Aug. 21, 2026) — 28% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLLN BillionToOne Inc BLLN
15 GF Score
Price $95.05
! 4 Warning Signs
View Full Analysis

What is BillionToOne PE Ratio without NRI?

BillionToOne BLLN -0.25% 15 PE Ratio without NRI is 149.92 as of Aug. 21, 2026, which is 28% below its 10-year median of 209.32. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 97 Medical Diagnostics & Research companies, BillionToOne ranks worse than 92.78% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-08-21), BillionToOne's share price is $95.05. BillionToOne's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $0.63. Therefore, BillionToOne's PE Ratio without NRI for today is 149.92.

During the past 3 years, BillionToOne's highest PE Ratio without NRI was 1849.18. The lowest was 147.21. And the median was 209.32.

BillionToOne's EPS without NRI for the three months ended in Jun. 2026 was $0.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $0.63.

As of today (2026-08-21), BillionToOne's share price is $95.05. BillionToOne's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.63. Therefore, BillionToOne's PE Ratio (TTM) for today is 149.92.

Good Sign:

BillionToOne Inc stock PE Ratio (=150.27) is close to 1-year low of 147.21.

During the past years, BillionToOne's highest PE Ratio (TTM) was 1849.18. The lowest was 147.21. And the median was 209.32.

BillionToOne's EPS (Diluted) for the three months ended in Jun. 2026 was $0.15. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.63.

BillionToOne's EPS (Basic) for the three months ended in Jun. 2026 was $0.17. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.73.


BillionToOne  (NAS:BLLN) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


BillionToOne PE Ratio without NRI Related Terms


BillionToOne PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for BillionToOne's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BillionToOne PE Ratio without NRI Chart

BillionToOne Annual Data
Trend Dec23 Dec24 Dec25
PE Ratio without NRI
N/A N/A 584.57

BillionToOne Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only N/A N/A 584.57 165.15 189.24

BLLN vs TWST, SHC, RDNT: PE Ratio without NRI Comparison

For the Diagnostics & Research subindustry, BillionToOne's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BillionToOne PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where BillionToOne's PE Ratio without NRI falls into.


BLLN
15GF Score
BillionToOne Inc BLLN
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

BillionToOne's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=95.05/0.634
=149.92

BillionToOne's Share Price of today is $95.05.
BillionToOne's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.63.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 149.92 mean?
BillionToOne (BLLN) has a PE Ratio without NRI of 149.92 as of Aug. 21, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on BillionToOne and its competitors. This is 28% below median its historical median of 209.32. Over the past decade, BillionToOne's PE Ratio without NRI has ranged from 147.21 to 1,849.18. According to the industry distribution chart, BillionToOne ranks #90 out of 97 companies in the Medical Diagnostics & Research industry, placing it in the top 92.8%.
Is BillionToOne's PE Ratio without NRI too high?
BillionToOne's current PE Ratio without NRI of 149.92 is 28% below median its 10-year median of 209.32. Over the past 10 years, this metric has ranged from a low of 147.21 to a high of 1,849.18. The Medical Diagnostics & Research industry median PE Ratio without NRI is 30.96. BillionToOne's value of 149.92 is 384.2% above this industry median. Based on the distribution chart, BillionToOne ranks #90 out of 97 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's PE Ratio without NRI compare to TWST and SHC?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #90 out of 97 companies for PE Ratio without NRI. This places BillionToOne in the lower half of its industry. The industry median PE Ratio without NRI is 30.96. BillionToOne's value of 149.92 is 384.2% above this benchmark. Historically, BillionToOne's own PE Ratio without NRI has ranged from 147.21 to 1,849.18 over the past decade. While the company's 10-year median is 209.32 vs. the industry median of 30.96, BillionToOne has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Diagnostics & Research company?
The median PE Ratio without NRI among Medical Diagnostics & Research companies is 30.96, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current PE Ratio without NRI of 149.92 is 384.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median PE Ratio without NRI is 30.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current PE Ratio without NRI is 149.92, which is 28% below median its own 10-year median of 209.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current PE Ratio without NRI of 149.92. The current PE Ratio without NRI is 149.92, which is 28% below median its 10-year median of 209.32 and 384.2% above the Medical Diagnostics & Research industry median of 30.96. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For BillionToOne (BLLN), the current PE Ratio without NRI is 149.92 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score

Get the complete analysis for BLLN

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$95.05
Price